Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

A.M. Lincoff; J.C. Tardif; B. Neal; S.J. Nicholls; L. Ryden; G.G. Schwartz; K. Malmberg; J.B. Buse; R.R. Henry; H. Wedel; A. Weichert; R. Cannata; D.E. Grobbee

doi:10.1016/j.ahj.2013.05.013

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

A.M. Lincoff, J.C. Tardif, B. Neal, S.J. Nicholls, L. Ryden, G.G. Schwartz, K. Malmberg, J.B. Buse, R.R. Henry, H. Wedel, A. Weichert, R. Cannata, D.E. Grobbee

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	429-434
Number of pages	6
Journal	American Heart Journal
Volume	166
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2013.05.013
Publication status	Published - 2013

Access to Document

10.1016/j.ahj.2013.05.013

http://www.ncbi.nlm.nih.gov/pubmed/24016490

Cite this

Lincoff, A. M., Tardif, J. C., Neal, B., Nicholls, S. J., Ryden, L., Schwartz, G. G., Malmberg, K., Buse, J. B., Henry, R. R., Wedel, H., Weichert, A., Cannata, R., & Grobbee, D. E. (2013). Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. American Heart Journal, 166(3), 429-434. https://doi.org/10.1016/j.ahj.2013.05.013

@article{639f6793d9a84e3286e0b8b295e892e1,

title = "Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.",

author = "A.M. Lincoff and J.C. Tardif and B. Neal and S.J. Nicholls and L. Ryden and G.G. Schwartz and K. Malmberg and J.B. Buse and R.R. Henry and H. Wedel and A. Weichert and R. Cannata and D.E. Grobbee",

year = "2013",

doi = "10.1016/j.ahj.2013.05.013",

language = "English",

volume = "166",

pages = "429--434",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "3",

}

Lincoff, AM, Tardif, JC, Neal, B, Nicholls, SJ, Ryden, L, Schwartz, GG, Malmberg, K, Buse, JB, Henry, RR, Wedel, H, Weichert, A, Cannata, R & Grobbee, DE 2013, 'Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.', American Heart Journal, vol. 166, no. 3, pp. 429-434. https://doi.org/10.1016/j.ahj.2013.05.013

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. / Lincoff, A.M.; Tardif, J.C.; Neal, B. et al.
In: American Heart Journal, Vol. 166, No. 3, 2013, p. 429-434.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

AU - Lincoff, A.M.

AU - Tardif, J.C.

AU - Neal, B.

AU - Nicholls, S.J.

AU - Ryden, L.

AU - Schwartz, G.G.

AU - Malmberg, K.

AU - Buse, J.B.

AU - Henry, R.R.

AU - Wedel, H.

AU - Weichert, A.

AU - Cannata, R.

AU - Grobbee, D.E.

PY - 2013

Y1 - 2013

U2 - 10.1016/j.ahj.2013.05.013

DO - 10.1016/j.ahj.2013.05.013

M3 - Article

C2 - 24016490

SN - 0002-8703

VL - 166

SP - 429

EP - 434

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Ryden L, Schwartz GG et al. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. American Heart Journal. 2013;166(3):429-434. doi: 10.1016/j.ahj.2013.05.013